Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 1;40(7):740-751.
doi: 10.1200/JCO.21.01784. Epub 2022 Jan 7.

Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance)

Affiliations

Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance)

En Cheng et al. J Clin Oncol. .

Abstract

Purpose: Current tools in predicting survival outcomes for patients with colon cancer predominantly rely on clinical and pathologic characteristics, but increasing evidence suggests that diet and lifestyle habits are associated with patient outcomes and should be considered to enhance model accuracy.

Methods: Using an adjuvant chemotherapy trial for stage III colon cancer (CALGB 89803), we developed prediction models of disease-free survival (DFS) and overall survival by additionally incorporating self-reported nine diet and lifestyle factors. Both models were assessed by multivariable Cox proportional hazards regression and externally validated using another trial for stage III colon cancer (CALGB/SWOG 80702), and visual nomograms of prediction models were constructed accordingly. We also proposed three hypothetical scenarios for patients with (1) good-risk, (2) average-risk, and (3) poor-risk clinical and pathologic features, and estimated their predictive survival by considering clinical and pathologic features with or without adding self-reported diet and lifestyle factors.

Results: Among 1,024 patients (median age 60.0 years, 43.8% female), we observed 394 DFS events and 311 deaths after median follow-up of 7.3 years. Adding self-reported diet and lifestyle factors to clinical and pathologic characteristics meaningfully improved performance of prediction models (c-index from 0.64 [95% CI, 0.62 to 0.67] to 0.69 [95% CI, 0.67 to 0.72] for DFS, and from 0.67 [95% CI, 0.64 to 0.70] to 0.71 [95% CI, 0.69 to 0.75] for overall survival). External validation also indicated good performance of discrimination and calibration. Adding most self-reported favorable diet and lifestyle exposures to multivariate modeling improved 5-year DFS of all patients and by 6.3% for good-risk, 21.4% for average-risk, and 42.6% for poor-risk clinical and pathologic features.

Conclusion: Diet and lifestyle factors further inform current recurrence and survival prediction models for patients with stage III colon cancer.

PubMed Disclaimer

Conflict of interest statement

En ChengStock and Other Ownership Interests: Pfizer Fang-Shu OuConsulting or Advisory Role: SC Liver Research Consortium Leonard B. SaltzResearch Funding: Taiho Pharmaceutical Robert J. MayerConsulting or Advisory Role: Bayer Renaud WhittomConsulting or Advisory Role: AstraZenecaResearch Funding: Canadian Cancer Trials Group (Inst) Al BensonConsulting or Advisory Role: Merck Sharp & Dohme, Array BioPharma, Bristol Myers Squibb, Samsung Bioepis, Pfizer, HalioDx, AbbVie, Janssen Oncology, Natera, Apexigen, Artemida Pharma, Xencor, Therabionic, Mirati Therapeutics, Boston ScientificResearch Funding: Infinity Pharmaceuticals (Inst), Merck Sharp & Dohme (Inst), Taiho Pharmaceutical (Inst), Bristol Myers Squibb (Inst), Celgene (Inst), Rafael Pharmaceuticals (Inst), MedImmune (Inst), Xencor (Inst), Astellas Pharma (Inst), Amgen (Inst), Syncore (Inst), Elevar Therapeutics (Inst), Tyme Inc (Inst), ST Pharm (Inst), ITM Solucin (Inst) Daniel AtienzaEmployment: US Oncology Hedy KindlerHonoraria: AstraZenecaConsulting or Advisory Role: AstraZeneca, Bristol Myers Squibb, Deciphera, Novocure, Seattle Genetics, InhibrxResearch Funding: Aduro Biotech (Inst), AstraZeneca (Inst), GlaxoSmithKline (Inst), Merck (Inst), Verastem (Inst), Bristol Myers Squibb (Inst), Polaris (Inst), Deciphera (Inst), Inhibrx (Inst), Roche/Genentech (Inst), Tesaro (Inst), Macrogenics (Inst), Leap Therapeutics (Inst), Fibrogen (Inst), Vivace Therapeutics (Inst), Constellation Pharmaceuticals (Inst), Harpoon therapeutics (Inst), Bayer (Inst), Seattle Genetics (Inst), Blueprint Medicines (Inst)Travel, Accommodations, Expenses: AstraZeneca Kimmie NgConsulting or Advisory Role: Seattle Genetics, X-Biotix Therapeutics, Array BioPharma, BiomX, Bicara TherapeuticsResearch Funding: Pharmavite (Inst), Revolution Medicines (Inst), Evergrande Group (Inst), Janssen (Inst) Cary P. GrossResearch Funding: Johnson & Johnson (Inst), AstraZeneca (Inst), GenentechUncompensated Relationships: Genentech (Inst) Jeffrey A. MeyerhardtHonoraria: Cota Healthcare, Taiho PharmaceuticalResearch Funding: Boston Biomedical (Inst) Charles S. FuchsEmployment: Genentech/RocheLeadership: CytomX Therapeutics, Evolveimmune TherapeuticsStock and Other Ownership Interests: CytomX Therapeutics, Entrinsic Health, Evolveimmune Therapeutics, Roche/GenentechConsulting or Advisory Role: Sanofi, Merck, Entrinsic Health, Agios, Taiho Pharmaceutical, Genentech/Roche, CytomX Therapeutics, Unum Therapeutics, Bain Capital, Lilly, Amylin, Daiichi-Sankyo, Evolveimmune Therapeutics, AstraZeneca, AstraZenecaExpert Testimony: Lilly, AmylinNo other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Nomogram for 5-year DFS. BMI, body mass index; COX-2, cyclooxygenase-2; CRC, colorectal cancer; DFS, disease-free survival; ECOG, Eastern Cooperative Oncology Group; MET, metabolic equivalent task; T/F, transverse/flexure.
FIG 2.
FIG 2.
Nomogram for 5-year OS. BMI, body mass index; COX-2, cyclooxygenase-2; CRC, colorectal cancer; ECOG, Eastern Cooperative Oncology Group; MET, metabolic equivalent task; OS, overall survival; T/F, transverse/flexure.
FIG 3.
FIG 3.
(A) Five-year predicted disease-free survival rates of patients with different clinical, pathologic, diet, and lifestyle characteristics. (B) Five-year predicted overall survival rates of patients with different clinical, pathologic, diet, and lifestyle characteristics. DFS, disease-free survival; OS, overall survival.

References

    1. Siegel RL, Miller KD, Fuchs HE, et al. : Cancer statistics, 2021. CA Cancer J Clin 71:7-33, 2021 - PubMed
    1. Akagi T, Inomata M: Essential updates 2018/2019: Essential advances in surgical and adjuvant therapies for colorectal cancer. Ann Gastroenterol Surg 4:39-46, 2020 - PMC - PubMed
    1. Howlader N, Noone AM, Krapcho M, et al. (eds): SEER Cancer Statistics Review, 1975-2016. Bethesda, MD, National Cancer Institute, 2019. https://seer.cancer.gov/csr/1975_2016/
    1. Bockelman C, Engelmann BE, Kaprio T, et al. : Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature. Acta Oncol 54:5-16, 2015 - PubMed
    1. Osterman E, Glimelius B: Recurrence risk after up-to-date colon cancer staging, surgery, and Pathology: Analysis of the entire Swedish population. Dis Colon Rectum 61:1016-1025, 2018 - PubMed

Publication types

MeSH terms